Comparison of the immunotherapy of the CIK cell, LAK cell and PBLS cell mediated by anti-EGFR/anti-CD3 bispecific antibody on the mice borne human gastric cancer

Objective To investigate the effect of the immunotherapy of CIK cell, LAK cell and PBLS cell mediated by anti-EGFR/anti-CD3 bispecific antibody (BsAb) respectively on the mice borne human gastric cancer and provide experimental evidence for therapeutic strategy in treating gastric cancer. Methods The mAbs of anti-CD3 and anti-EGFR were cross-linked to prepare the BsAb by chemical synthesis. The experimental therapy on the mice borne SGC7901 human gastric cancer was performed, and then the comparisons of the curative activity among the CIK group, LAK group and PBLS group were conducted in vivo. Results The mean tumor reduction rate of the administration of CIK cells directed by anti-EGFR/anti-CD3 BsAb was (64.9±7.7) ％ and higher than those of LAK cells or PBLS targeted by anti-EGFR/anti-CD3 BsAb [(43.5±8.2) ％ and (39.7±6.5) ％] (P ＜ 0.05).The mean tumor weight of the administration of CIK cells directed by anti-EGFR/anti-CD3 BsAb was (473.9±37.7) mg at the end of therapy and was lower than those of LAK cells or PBLS targeted by anti-EGFR/anti-CD3 BsAb [(764.6±88.3) mg and (829.1±104.4) mg](P ＜ 0.05). Conclusion The CIK cell mediated by anti-EGFR/anti-CD3 BsAb could have better curative effect than other effector cells on gastric cancer in vivo. Key words: Gastric neoplasms; Antibodies,bispecific; Cytokine-induced killer cells; Killer cells,lymphokine-activated; Immunotherapy